<?xml version="1.0" encoding="UTF-8"?>
<results title="testTrace">
 <result pre="visit http://creativecommons.org/licenses/by/4.0/. Convalescent plasma therapy holds promise as a transient" exact="treatment" post="for COVID-19. Yet, blood products are important sources of"/>
 <result pre="for COVID-19. Yet, blood products are important sources of HIV" exact="infection" post="in low- and middle-income nations. Great care must be"/>
 <result pre="the concept of passive immunity. Individuals who recover from SARS-CoV-2" exact="infection" post="have, in principle, developed neutralizing antibodies against the virus2."/>
 <result pre="from COVID-19 and infusing it into someone with an ongoing" exact="infection" post="would confer the plasma recipient with antibodies to combat"/>
 <result pre="combat the virus3. Of note, this is an immediate transient" exact="treatment" post="and does not replace the long-lasting immune memory generated"/>
 <result pre="have been shown to represent an important source of HIV" exact="infection" post="in many low- and middle-income countries, being associated with"/>
 <result pre="(UNDP) and the World Health Organization (WHO) have subsidized molecular" exact="testing" post="in the developing world. One such program, the introduction"/>
 <result pre="program, the introduction of â€œall-in-one cartridgeâ€� systems for RNA sample" exact="isolation" post="and PCR-based testing, has been used for HIV and"/>
 <result pre="run, severely limiting its utility for COVID-19 and HIV PCR-based" exact="testing" post="in larger communities. Moreover, governmental laboratories with RNA testing"/>
 <result pre="PCR-based testing in larger communities. Moreover, governmental laboratories with RNA" exact="testing" post="capabilities are currently saturated in many low- and middle-income"/>
 <result pre="many low- and middle-income countries11, leaving administrators to decide between" exact="testing" post="for COVID-19 or HIV. Regulations worldwide have forbidden paid"/>
 <result pre="local pay-for-plasma schemes15. Rapid and affordable antibody-based HIV and COVID-19" exact="testing" post="capacity must be escalated in the developing world. One"/>
 <result pre="tests from abroad10. Centers with a proven track record of" exact="testing" post="for endemic contagious diseases in the developing world exist,"/>
 <result pre="plasmids, purified antibodies) may be more desirable than already assembled" exact="testing" post="kits. Importantly, conventional antibody-based HIV testing may miss early"/>
 <result pre="desirable than already assembled testing kits. Importantly, conventional antibody-based HIV" exact="testing" post="may miss early infection18. Hence, methods to detect viral"/>
 <result pre="summary, convalescent plasma therapy holds promise as an emergency transient" exact="treatment" post="for critical COVID-19 patients. Nevertheless, it is of utmost"/>
 <result pre="can endanger entire communities. In scenarios of scarce blood-borne pathogen" exact="testing" post="capacities, few enforced regulations, and widespread misinformation and disease"/>
 <result pre="medRxiv.10.1101/2020.03.30.2004736 (2020). 3.Liu, S. T. H. et al. Convalescent plasma" exact="treatment" post="of severe COVID-19: a matched control study. medRxiv.10.1101/2020.03.30.20047365 (2020)."/>
 <result pre="8.NkengasongJLet Africa into the market for COVID-19 diagnosticsNature202058056510.1038/d41586-020-01265-032346145 9.NdlovuZet al.Multidisease" exact="testing" post="for HIV and TB using the GeneXpert platform: a"/>
 <result pre="serologic tests for Trypanosoma cruzi and the effectiveness of transfusional" exact="screening" post="strategies in a hyperendemic regionTransfusion20054555456110.1111/j.0041-1132.2005.04214.x15819677 17.LealYAFloresLLGarcia-CortesLBCedillo-RiveraRTorresJAntibody-based detection tests for"/>
 <result pre="effectiveness of transfusional screening strategies in a hyperendemic regionTransfusion20054555456110.1111/j.0041-1132.2005.04214.x15819677 17.LealYAFloresLLGarcia-CortesLBCedillo-RiveraRTorresJAntibody-based" exact="detection" post="tests for the diagnosis of Helicobacter pylori infection in"/>
 <result pre="strategies in a hyperendemic regionTransfusion20054555456110.1111/j.0041-1132.2005.04214.x15819677 17.LealYAFloresLLGarcia-CortesLBCedillo-RiveraRTorresJAntibody-based detection tests for the" exact="diagnosis" post="of Helicobacter pylori infection in children: a meta-analysisPLoS ONE20083e375110.1371/journal.pone.000375119015732"/>
 <result pre="regionTransfusion20054555456110.1111/j.0041-1132.2005.04214.x15819677 17.LealYAFloresLLGarcia-CortesLBCedillo-RiveraRTorresJAntibody-based detection tests for the diagnosis of Helicobacter pylori" exact="infection" post="in children: a meta-analysisPLoS ONE20083e375110.1371/journal.pone.000375119015732 18.HashidaSet al.Shortening of the"/>
 <result pre="a meta-analysisPLoS ONE20083e375110.1371/journal.pone.000375119015732 18.HashidaSet al.Shortening of the window period in" exact="diagnosis" post="of HIV-1 infection by simultaneous detection of p24 antigen"/>
 <result pre="18.HashidaSet al.Shortening of the window period in diagnosis of HIV-1" exact="infection" post="by simultaneous detection of p24 antigen and antibody IgG"/>
 <result pre="the window period in diagnosis of HIV-1 infection by simultaneous" exact="detection" post="of p24 antigen and antibody IgG to p17 and"/>
 <result pre="serum with ultrasensitive enzyme immunoassayJ. Virol. Methods199662435310.1016/0166-0934(96)02087-38910647 19.GootenbergJSet al.Nucleic acid" exact="detection" post="with CRISPR-Cas13a/C2c2Science201735643844210.1126/science.aam932128408723 20.GronowskiAMWho or what is SHERLOCK?EJIFCC20182920120430479604 21.CarossoGAFerreiraLMRMostajo-RadjiMAScientists as"/>
</results>
